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Introduction
Tissue hypoxia usually reflects a locally restricted oxygen
supply (ischemia) and/or an abnormal increase in oxygen
consumption. In clinical practice, hypoxia is related to a vari-
ety of pathological conditions including cancer, ischemic
heart disease and stroke. Locally advanced solid tumors
often have hypoxic or anoxic regions distributed heteroge-
neously throughout the tumor as a result of a structurally or
functionally abnormal vasculature. Tumor hypoxia is com-
monly associated with a poor prognosis after radiation and
chemotherapy, and hypoxia can influence many aspects of
tumor proliferation, such as growth, apoptosis, angiogenesis
and metastasis.[1,2]
In 1955, 2-nitroimidazole was shown to be active against
certain anaerobic bacterial infections.[3] Later it was discov-
ered that 2-nitroimidazole analogues could be used to sensi-
tize hypoxic tumors to ionizing radiation.[4,5] Further re-
search on the mechanism of action of this compound re-
vealed that it was capable of accumulating in hypoxic tissue
due to selective enzyme-mediated reduction of the nitro
group under low oxygen conditions.[6] The diverse bioactivity
of nitroimidazoles and related nitroaromatic compounds has
the same underlying mechanism; the activities of these com-
pounds depend on the redox potential of the nitro group.[7]
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differentiate hypoxic versus normoxic
tissue could have an immediate impact
on therapy choices. In this work, the
gadolinium complex of 1,4,7,10-tetraa-
za-1,4,7,10-tetraacetate (DOTA) with
a 2-nitroimidazole attached to one car-
boxyl group via an amide linkage was
prepared, characterized and tested as
a hypoxia-sensitive MRI agent. A con-
trol complex, Gd(DO3A-monobutyla-
mide), was also prepared in order to
test whether the nitroimidazole side-
chain alters either the water proton T1
relaxivity or the thermodynamic stabili-
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these complexes were lower than that
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The resulting parameters (r1=
6.38 mm1 s1 at 20MHz, tM=0.71 ms,
tR=141 ps) determined for the nitroi-
midazole derivative closely parallel
those of other Gd(DO3A-monoamide)
complexes of similar molecular size. In
vitro MR imaging experiments with 9L
rat glioma cells maintained under ni-
trogen (hypoxic) versus oxygen (nor-
moxic) gas showed that both agents
enter cells but only the nitroimidazole
derivative was trapped in cells main-
tained under N2 as evidenced by an ap-
proximately twofold decrease in T1
measured for hypoxic cells versus nor-
moxic cells exposed to this agent.
These results suggest that the nitroimi-
dazole derivative might serve as a mo-
lecular reporter for discriminating hy-
poxic versus normoxic tissues by MRI.
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The first step of this intracellular process involves the one-
electron reduction of the nitro group to a radical anion,
which undergoes further reduction in hypoxic cells but is
rapidly oxidized back to the nitro compound under normox-
ic conditions. The reduction potential of the nitro group in
nitroimidazoles is sensitive to its position in the imidazole
ring and this correlates with hypoxia sensitivity.[8] Given the
prospect of nitroimidazole as a platform for hypoxia-homing
probes, several radiolabeled nitroimidazole derivatives and
related compounds have been tested as imaging probes of
hypoxic tissue, in vivo.[9] Most prominent among theses have
been the 18F labeled fluoromisonidazole (18F-FMISO)[10] for
PET imaging and the 99mTc labeled propylene amineoxime
(BMS181321)[11] for SPECT imaging. Cyclen (1,4,7,10-tetraa-
zacyclododecane)-based nitroimidazole derivatives tagged
with 67GaIII, 153GdIII or 177LuIII have shown only moderate
tumor localization.[12–14] Although several multifluorinated
derivatives of 2-nitroimidazole have been synthesized and
used to assess tumor hypoxia by 19F NMR spectroscopy,
GdIII-based nitroimidazole derivatives for 1H MRI have not
been reported.[15–17] Although MRI is considerably less sensi-
tive than nuclear medicine for molecular imaging, it does
offer the advantage of wide clinical availability, lack of radi-
ation and high resolution anatomical images. For these rea-
sons, we initiated a program to develop gadolinium-based 2-
nitroimidazole derivatives and to evaluate the potential of
such agents for detecting hypoxic cells by MRI.
Results and Discussion
Ligand design and synthesis : DOTA (1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid) was selected as the che-
late for the conjugation to 2-nitroimidazole because GdIII
complexes with DOTA-like ligands have high thermody-
namic stability, are kinetically inert and have favorable re-
laxation properties.[18,19] The 2-nitroimidazole vector was se-
lected based on its one-electron reduction potential, known
to fall in the range of 330 to 450 mV, which allows for its
entrapment and exclusive reduction under hypoxic condi-
tions as it has been previously reported in the literature by
many scientists (vide supra). Since conjugation of DOTA to
a targeting vector via a single carboxyl group is relatively
straightforward,[20] a 2-nitroimidazole moiety with an ex-
tended side-chain containing a primary amino group was
chosen for conjugation (Scheme 1). This design affords
a neutral GdIII complex, which would hopefully help facili-
tate cellular uptake. It was anticipated that the relatively
long linkage between Gd(DO3A-monoamide) unit and the
nitroimidazole moiety in 3 would minimize any unwanted
interference between the GdIII coordination sphere and the
nitroimidazole unit and, at the same time, increase complex
lipophilicity. In addition, the linker does not contain groups
that can engage in prototropic equilibria at physiological pH
and should therefore not affect the redox potential of the ni-
troimidazole unit.[8,21] The synthesis of the target ligand is
outlined in Scheme 1.
The protected DO3A-monoamide derivative 1 was ob-
tained by alkylating DO3A-tris(tert-butyl ester) with methyl
chloroacetate and treating the resulting methyl ester with
excess diaminobutane (putrescine) following a slight modifi-
cation of a published procedure (see the Supporting Infor-
mation).[22] Nitroimidazoyl hexanoic acid (2) was synthesized
by alkylation of 2-nitroimidazole with ethyl bromohexa-
noate followed by the cleavage of the ethyl group in concen-
trated HCl, as previously reported.[23] The imidazoyl acid 2
and macrocyclic amine 1 were then coupled by using stan-
dard HBTU/HOBt chemistry.[24,25] The tert-butyl protecting
groups of the intermediate ester were cleaved by using tri-
fluoroacetic acid (TFA) and the crude product was purified
by HPLC to give pure 3 (28% yield). Gd(3) was obtained in
quantitative yield by treatment of 3 with GdCl3 at pH 6.
Ligand protonation and complex stability constants : The co-
ordination environment (four macrocyclic N-donor atoms,
three carboxylate O-donor atoms and one amide O-donor
atom) provided by ligand 3 is typical of a DOTA- and
DO3A-bioconjugate in which the chelator is attached to the
biomolecule through one of the acetate pendant arms of the
ligand.[20] Despite the widespread use of these ligands to
chelate Gd3+ for MRI and various radioactive lanthanide
ions for radiopharmaceutical applications, only a limited
number of studies have appeared on the thermodynamic sta-
bility, formation and dissociation kinetics of DO3A-monoa-
mides.[26,27] Here, we report the thermodynamic stabilities of
the Ce(3), Gd(3) and Yb(3) and the results of 1H and
17O NMR relaxometric studies of Gd(3). The results are also
compared to corresponding data for Ce(6), Gd(6) and
Yb(6).
Generally, pH potentiometry is considered the gold stan-
dard technique for determining the protonation constants of
polyaminopolycarboxylate ligands and thermodynamic sta-
bility constants of complexes formed with various metal
ions. The protonation constants obtained from fitting the
pH-potentiometric data for ligands 3 and 6 are presented in
Table 1 along with the literature data for DOTA (4) and
Scheme 1. Synthesis route to ligand 3 (yield: 28%).
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two amide derivatives, DO3A-monopropylamide (5) and
DOTA-tetramethylamide (7). The trends found for the pro-
tonation constants of these ligands are similar, except for
DOTA-tetramethylamide (7; Scheme 2). For DOTA and
DO3A-monoamide derivatives (3 and 6), the first two pro-
tonation constants, which have been traced to protonation
at ring nitrogen atoms positioned trans to one another, are
relatively high, whereas the remaining logKi
H values (re-
flecting protonation of the carboxylates) are much lower.
For the monoamide ligands studied here (3 and 6) five pro-
tonation steps were observed in the pH range of 2–12. The
total basicity of these ligands (expressed as the sum of the
protonation constants, logb4) is lower than that of DOTA,
reflecting the lower basicity of the macrocyclic N atoms.[28,29]
The protonation constants of 6 as determined previously by
pH-potentiometry in 0.1m Me4NCl (logb4=27.94) were
found to be somewhat higher than the values measured here
in 1.0m KCl (logb4=26.54).
[30] This can be attributed to the
formation of a weak potassium complex in the presence of
1.0m KI ions (a similar decrease in basicity was observed for
DOTA when the protonation constants were measured in
the presence of KCl versus Me4NCl).
[31] Interestingly, the
first protonation constant of 3 is slightly lower (0.4 logK
units) than that of 6, presumably reflecting the elongated
side arm on the amide. A similar decrease in basicity was
also observed for some alkyl-EDTA derivatives for which
an increase in the length of the alkyl substituent
had a noticeable effect on the first protonation con-
stant (Table S1 in the Supporting Information).
The formation equilibria between these macrocy-
clic ligands and the LnIII ions cannot be studied by
direct pH potentiometric titration because of slow
formation kinetics. Hence, the stability constants
were determined by the use of the “out-of-cell”
technique with separate samples for each titration
point (total of 16 points). The stability constants of
some Ln(3) and Ln(6) complexes, assuming forma-
tion of only 1:1 complexes, are listed in Table 2.
The standard deviations associated with these con-
stants significantly decreased when the formation of
monoprotonated species (LnLH) was also taken into consid-
eration in the calculations. This suggests that protonation of
the complexes also occurs under these conditions. The Ce(6)
system was an exception, as the inclusion of the protonated
species in the equilibrium model for this complex resulted in
a significant increase in the standard deviation of fitted pa-
rameters.
As expected, the stabilities of all LnIII complexes increase
with decreasing lanthanide ion size, CeIII<GdIII<LuIII
(Table 2).[37] The stabilities of all Ln(3) complexes were simi-
lar to the corresponding Ln(6) complexes, as expected for
similar DO3A-monoamide structures. This indicates that in-
corporation of the elongated nitroimidazole-containing
pendant arm does little to alter complex stability. However,
these complexes are about four orders of magnitude less
stable than the corresponding Ln ACHTUNGTRENNUNG(DOTA) complexes due
to the substitution of a carboxylate in DOTA for the weaker
amide donor atom in 3 and 6. This is also reflected in the
total basicity of 3 and 6 compared to DOTA. Further substi-
tution of acetate arms for amides resulted in even lower sta-
bilities as illustrated by the stability of the LnIII complexes
of 7. It is worth noting that the stability constant values
measured in the presence of KCl represent a lower limit
since these calculations assume no significant interaction be-
tween the ligands and KI ions—likely an invalid assumption.
These results indicate that DO3A-monobutylamide (6)
serves as a good model for the nitroimidazole ligand, 3, and
other similar DOTA- or DO3A-bioconjugate systems.
Table 1. Protonation constants[a] of 3 and some ligands of similar structure, 1m KCl,
25 8C.
logK 3[b] 4 5[e] 6[b] 7[h]
logK1
H 9.78(2) 12.09;[c] 12.6[d] 9.6 10.17(1), 12.22,[f] 10.73[g] 9.56
logK2
H 9.05(3) 9.67;[c] 9.70[d] 9.2 9.02(1), 8.90,[f] 9.05[g] 5.95
logK3
H 4.53(4) 4.55;[c] 4.50[d] 4.4 4.41(1), 4.34,[f] 4.53[g] –
logK4
H 3.17(5) 4.09;[c] 4.14[d] 1.7 2.94(1), 2.49,[f] 3.32[g] –
logK5
H 2.19(6) 2.32[d] – 1.99(1), 1.47,[f] 2.25[g] –
logb4 26.53 30.40;
[c] 30.94[d] 24.9 26.54, 27.94,[f] 27.63[g] 15.51[i]
[a] Standard deviations shown in parentheses; [b] this work, in KCl (1.0m) and at
25 8C; [c] in KCl (0.1m);[32] [d] in Me4NCl (1.0m);
[33] [e] in NaCl (0.1m);[26] [f] in
Me4NCl (0.1m);
[30] [g] the ionic strength was not controlled (25 8C);[34] [h] in KCl
(0.1m);[35] [i] the value refers to log b2, since this ligand has only two protonation con-
stants.
Scheme 2. The structures of DOTA (4), a DOTA-tetramethylamide (7)
and some DO3A-monoamide derivatives (5, 6 and 8) discussed in this
work.
Table 2. Thermodynamic stability constants and protonation constants of
lanthanide complexes of ligands 3–7, 25 8C.
LnIII Eq. 3[a] 4[c] 5[f] 6[a] 7[h]
CeIII
logKLn·L 19.2 ACHTUNGTRENNUNG(0.1) 23.39, 22.86
[d] – 19.26(4) 12.68
logKLnL·H
[b] – 2.5[d] – 2.65(5) –
GdIII
logKLn·L 20.93(9) 24.67, 25.3
[e] 20.1 21.29(1) 13.54
logKLnL·H 2.93(4) 2.3 – 2.57(1) –
LuIII
logKLn·L 21.51(9) 25.41, 25.0
[e] – 21.83(3)[g] 13.91
logKLnL·H 2.44(9) – – 2.33(4) –
[a] This work in KCl (1.0m); [b] logKLnL·H= [LnHL]/ ACHTUNGTRENNUNG[LnL][H
+];
[c] refs. [3637]; [d] data correspond to the LaIII complex; [e] refs. [3637];
[f] in NaCl (0.1m);[26] [g] data correspond to the YbIII complex; [h] in KCl
(1.0m).[35]
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Relaxometric studies : MRI contrast agents are typically
characterized by a T1 proton relaxivity (r1p) value. The relax-
ivity (r1p) of low molecular weight GdL that has rapid water
exchange kinetics is dominated by the inner-sphere contri-
bution (r1p
is). The Solomon–Bloembergen–Morgan (SBM)
theory of relaxivity predicts that r1p
is is dependent on several
parameters including the number of inner-sphere water mol-
ecules (q), the longitudinal relaxation time of the protons of
the water molecule(s) in the inner coordination sphere
(T1M
H), the residence time of the inner-sphere water mole-
cule(s) (tM) and the tumbling rate of the paramagnetic com-
plex in solution (tR, rotational correlation time).
[38] At clini-
cally relevant fields (1.5–3 T), the relaxivity is largely deter-
mined by tM and tR. These constants can be obtained by fit-
ting of variable temperature 17O NMR (tM) and
1H nuclear
magnetic relaxation dispersion (NMRD) data (tR).
[38–40] At
20MHz, 25 8C and pH 7, the relaxivity (r1p) of Gd(3) and
Gd(6) were 6.38 ACHTUNGTRENNUNG(0.04) and 5.05 ACHTUNGTRENNUNG(0.02) mm1 s1, respec-
tively, measured at 20MHz. The r1p value of Gd(3) is about
30% higher than that of Gd(6), reflecting its higher molecu-
lar weight (larger size) and consequently longer rotational
correlation time (tR). The relaxivity of Gd(6) is nearly the
same as that of Gd(8) (r1p=5.0 mm
1 s1, 25 8C, 20MHz),
a Gd-complex of similar molecular weight and size.[41]
Temperature dependence of relaxivity : The relaxivities of
Gd(3) and Gd(6) were also measured at 37 8C (20MHz)
and found to be only slightly lower (5.25ACHTUNGTRENNUNG(0.05) and 4.12-
ACHTUNGTRENNUNG(0.02) mm1 s1, respectively) than the values measured at
25 8C. The relaxivity of Gd ACHTUNGTRENNUNG(DOTA) has a similar tempera-
ture dependence at this field, decreasing from 4.7 to
3.6 mm1 s1 as the temperature
is increased from 25 to 37 8C.
This behavior is expected for
fast inner-sphere water ex-
change systems. It has been
shown that the relaxivity of
low-molecular-weight Gd-poly-
aminopolycarboxylate com-
plexes the bound water life-
times of which fall into the fast
exchange regime (T1M@tM) de-
creases exponentially with in-
creasing temperature due to
a decrease of the contribution
of both r1p
is (the residence time
of the bound water molecule
decreases) and r1p
os (the diffu-
sion rate of the water molecules
increases on the surface of the
complex). This has been ob-
served for the GdIII complexes
of DOTA-like ligands that have
two inner-sphere water mole-
cules (q=2; DO3A, PCTA)
and consequently fast water ex-
change rates.[27,41,42] However,
as the bound water lifetime approaches the slow exchange
condition (T1MtM), the relaxivity becomes exchange limit-
ed and its temperature dependence is less pronounced.[43,44]
Variable temperature 17O NMR spectroscopy: The water ex-
change dynamics in Gd(3) and Gd(6) were studied by varia-
ble temperature 17O NMR measurements. The temperature
dependent profiles of the water 17O NMR transverse relaxa-
tion rates for Gd(3) and Gd(6) (Figure 1) are similar to
those reported previously for GdIII complexes of other small
molecular weight complexes, such as Gd(7).[41] The maxi-
mum in the R2p versus temperature curves for Gd(3) and
Gd(6) were observed at about the same temperature as that
reported previously for Gd(8) whereas the maximum ob-
served for Gd ACHTUNGTRENNUNG(DOTA) is shifted to lower temperatures, re-
flecting faster water exchange.[41,42] The residence time (tM)
of the inner-sphere water molecule was determined by fit-
ting these data to Swift–Connick theory.[45,44] The value
found here for Gd(3) (0.71 ms; Table 3) is about 50% of that
found for Gd(8) (1.3 ms) and about four-times longer than
that found for Gd ACHTUNGTRENNUNG(DOTA) (tM=0.23 ms at 298 K).
[38,41]
These values are consistent with the empirical observation
that substitution of one carboxylate for an amide results in
an approximately three- to fourfold decrease in the metal
bound water exchange rate in Ln complexes of polyamino-
polycarboxylate-type ligands.[46] The relatively long water
residence times suggest that the water exchange in these
complexes likely occur through a dissociative mechanism.[46]
Magnetic field dependence : The magnetic field dependence
of the proton relaxation rates (NMRD profiles) was also
Figure 1. Top row: temperature dependence of the transverse water 17O NMR relaxation rates at 14.1 T and
pH 7 for 21 and 19 mm solutions of Gd(3) (left) and Gd(6) (right), respectively. Bottom row: NMRD profiles
of the 1 mm solutions of Gd(3) (left) and Gd(6) (right) at pH 7. The solid and dashed curves in the lower part
represent the inner- and outer-sphere contributions to the overall relaxivity, respectively.
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A. D. Sherry, G. Tircs et al.
measured for Gd(3) and Gd(6) at 25 8C and pH 7 (Figure 1).
Among other relaxation parameters, the rotational correla-
tion time (tR) can be determined from the magnetic field
dependence of the longitudinal relaxation rate of the com-
plex.
In a typical NMRD experiment, a field-cycling relaxome-
ter is used to measure the longitudinal relaxation rates of
the solvent protons in the presence of the paramagnetic
complex over a continuum of magnetic fields that range
from 0.01MHz up to approximately 70MHz. Normally, tM
is independently determined by variable temperature
17O NMR spectroscopy, whereas the inner-sphere relaxivity
parameters are obtained by fitting the NMRD profiles to
the Solomon–Bloembergen–Morgan equations and the
outer-sphere parameters are determined by fitting the data
to Freeds equations.[47,48] The solid curves through the ex-
perimental data points (Figure 1) represent the best fit cal-
culated values obtained by use of the relaxation parameters
summarized in Table 3. The NMRD profile of both com-
plexes show a single dispersion centered near 4MHz with
two plateaus in the low and high magnetic field regions.
(The rotational correlation times of the complexes Gd(6)
(tR=86 ps) and Gd(8) (tR=70 ps) are similar, whereas the
tR value of the complex Gd(3) (141 ps) is about twice as
high as that of Gd(8).)[41] Obviously, the long pendant arm
in Gd(3) slows molecular rotation in this complex resulting
in a higher relaxivity. The inner- and outer-sphere contribu-
tion to the r1p relaxivity of Gd(3) and Gd(6) could also be
estimated from the fitting of the NMRD profile (Figure 1).
At 25 8C and 20MHz, the inner-sphere relaxivity (r1p
is) of
Gd(3) (4.0 mm1 s1) is almost twice as high as that of Gd(6)
(2.4 mm1 s1) due to its slower tumbling rate. On the other
hand, as expected, the contribution of the outer-sphere
water molecules to the overall relaxivity (r1p
os) is compara-
ble (2.5 mm1 s1) for both complexes. This value is also in
good agreement with the r1p value of Gd(7) (r1p=
2.5 mm1 s1, 25 8C, 20MHz), a complex the water proton
longitudinal relaxation rate of which is dominated by the
outer-sphere relaxation due to the very slow exchange be-
tween the inner-sphere water molecule and the bulk
water.[49]
MRI of cells : Cellular uptake of Gd(3) (or Gd(6) as control)
under hypoxic versus normoxic conditions was first exam-
ined by using 9L rat glioma cells as an in vitro model. This
cell line has been extensively used in the past as a hypoxia
model in radiosensitivity studies under low oxygen condi-
tions.[52–54] In our experiments, hypoxia was induced in 9L
cells by exposing a plate of cells to nitrogen gas at a rate of
1 Lmin1 for 2 h at room temperature prior to the addition
of the complex. After this induction phase, the cells were in-
cubated with either 5 mm Gd(3) or Gd(6) for 2 h under
a continuous flow of nitrogen gas. The control consisted of
the same cells exposed to the same concentration of each
agent but by using a constant flow of air rather than nitro-
gen. In addition, a negative control was prepared in which
cells were incubated with PBS buffer alone (no gadolinium).
After the incubation period, the samples were washed with
PBS, detached from the culture plates with trypsin, centri-
fuged, and imaged immediately at 4.7 T. The T1-weighted
images and T1 maps for three samples: 1) negative control
(C), 2) normoxic incubation (N), and 3) hypoxic incubation
(H) of each complex are shown in Figure 2.
Table 3. Relaxation parameters calculated from the simultaneous fitting
of the temperature dependence of the water 17O transverse relaxation
rate and the NMRD profiles of Gd(3) and Gd(6).
Gd(3) Gd(6) Gd(8)[a]
r1p
298 [mm1 s1] 6.380.04 5.050.02 5.0
q 1 1 1
D2 [s21019] 1.90.1[b] 1.00.1[b] 1.4
tv
298 [ps] 587[b] 344[b] 40
tR
298 [ps] 1413[b] 862[b] 70
tM
298 [ps] 0.710.09[c] 0.660.05[c] 1.3
DHM [kJmol
1] 284[c] 403[c] 19
DHV [kJmol
1] 2510[c] 2810[c] 40
[a] Ref. [41]; [b] best-fit parameters obtained from the analysis of the
NMRD profile by using the standard value for the average distance be-
tween the metal and protons of the inner-sphere water molecule (a=
3.8 	), and 2.24105 cm2s1 for the self-diffusion coefficient of water
(D);[43,50] [c] best-fit parameters obtained from the analysis of the temper-
ature dependence of 17O NMR transverse relaxation rate in 21 and
19 mm solutions of Gd(3) and Gd(6), respectively, assuming a Gd3+–17O
scalar coupling constant of 3.8106 rads1 and a GdIII–17O distance of
2.5 	.[44,51]
Figure 2. In vitro MR imaging of 9L rat glioma cells after exposure to
either Gd(3) or Gd(6) (top). The T1-weighted images (TR=300 msec;
TE=10 msec) and T1 maps of negative control (C), normoxic (N) and hy-
poxic (H) cells. Relaxation rates (R1) for the packed cell layers (bottom);
*=p<0.05 compared to negative control (C); **=p<0.05 compared to
normoxic sample (N). A color version of Figure 2 is included in the Sup-
porting Information.
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If the nitroimidazole moiety in Gd(3) undergoes reduc-
tion and is trapped in hypoxic cells, then the accumulation
of Gd(3) should result in brighter proton images as a result
of the shortening of T1 of the bulk water by the intracellular
agent. As seen from the T1-weighted images in Figure 2, the
hypoxic sample (H) has higher signal intensity when com-
pared to the other two samples, whereas the normoxic and
negative control samples are indistinguishable. The T1 maps
also show that cells incubated with Gd(3) under normoxic
conditions have a somewhat shorter T1 than the negative
control cells. The average T1 values for the negative con-
trols, the normoxic and hypoxic incubation samples were
1.6 ACHTUNGTRENNUNG(0.2), 1.4 ACHTUNGTRENNUNG(0.1), and 0.8 ACHTUNGTRENNUNG(0.1) s, respectively. This illus-
trates that Gd(3) enters cells by passive diffusion in both
cell samples (normoxia and hypoxia) and a small amount of
complex likely gets trapped even in normoxic cells. Never-
theless, the hypoxic cell pellet displays the shortest T1 of the
three samples. Converting the values to relaxation rates
(0.64 ACHTUNGTRENNUNG(0.09), 0.74 ACHTUNGTRENNUNG(0.14) and 1.31 ACHTUNGTRENNUNG(0.33) s1, respectively)
highlights the differences in R1p.
Subtraction of the R1 value for the negative control (cells
only, no Gd(3)), yields R1p values of 0.10 and 0.67 s
1 for the
samples incubated with Gd(3) under normoxic and hypoxic
conditions, respectively. Thus, the hypoxic cells accumulate
approximately twofold more Gd(3) compared to normoxic
cells. In comparison, the distribution of T1 values found for
normoxic and hypoxic cells incubated with Gd(6) are signifi-
cantly different (p<0.05) from the negative control but not
from each other. The R1p values of for the samples are 0.45
and 0.56 s1 under normoxic and hypoxic conditions, respec-
tively. Although the two complexes (Gd(3) and Gd(6))
appear to accumulate to about the same extent in hypoxic
cells as the nitroimidazole derivative, only Gd(3) shows hy-
poxia selectivity. The higher uptake of Gd(6) indicates that
its uptake and retention is mediated by an oxygen-independ-
ent factor other than just passive diffusion. The higher
uptake of Gd(6) could reflect its lower molecular weight
and/or higher lipophilicity. Whatever the exact reasons for
the nonselective uptake of Gd(6), the important fact is that
this complex does not show hypoxia selectivity, whereas
Gd(3) exhibits selective hypoxia-mediated retention.
Conclusion
DO3A-monoamide conjugate of 2-nitroimidazole (ligand 3)
was synthesized and its complexes with GdIII and other lan-
thanide ions were characterized. As expected, the protona-
tion constants of this ligand and stability of the resulting lan-
thanide ion complexes are quite comparable to published
values for similar compounds. The ligand has a total of five
protonation steps in the pH range of 2–12; two of these are
assigned to the protonation of two macrocyclic nitrogen
atoms. The stability of the Ln(3) complexes ranges from
19.24 to 21.51 for CeIII to LuIII, about four orders of magni-
tude lower than that of the corresponding Ln ACHTUNGTRENNUNG(DOTA) com-
plexes. This is in accordance with the lower total basicity of
3 compared to DOTA. The r1p relaxivity, residence time of
the metal bound water molecule (tM) and rotational correla-
tion time (tR) of Gd(3) was determined by relaxivity meas-
urements, variable temperature 17O NMR spectroscopy and
proton nuclear magnetic relaxation dispersion (NMRD)
studies, and the data (r1p=6.38 mm
1 s1, tM=0.71 ms, tR=
141 ps) are in agreement with those obtained for other GdIII
complexes of similar size. In vitro MRI experiments with hy-
poxic 9L rat glioma cells revealed that Gd(3) is selectively
trapped in hypoxic cells as evidenced by a nearly twofold
contrast enhancement in the images of cells compared to
normoxic cells. This suggests that this nitroimidazole conju-
gate might be suitable for assessment of hypoxia, in vivo.
Preliminary MR imaging of tumor bearing rats indicates
that Gd(3) indeed accumulates largely in hypoxic tissues.[55]
Experimental Section
Abbreviations : MRI: magnetic resonance imaging; PET: positron emis-
sion tomography; SPECT: single photon emission computed tomography;
L: ligand; DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid; DO3A: 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid; PCTA:
pyclen triacetic acid; NMRD: nuclear magnetic resonance dispersion;
ROI: region of interest.
General : Details of all synthesis procedures, characterization of all inter-
mediates, preparation of the GdIII complexes, pH potentiometric titra-
tions of ligands and complexes are reported in the Supporting Informa-
tion.
Relaxivity and NMRD measurements : The T1 values were recorded at
20MHz (0.47 T), 25 8C and 37 8C by using a Stelar Spinmaster spectrom-
eter (Stelar, Italy) and a Maran Ultra relaxometer (Oxford Instruments,
UK) at 23MHz and 37 8C. Longitudinal relaxation times were measured
by using the inversion-recovery pulse sequence (1808-t-908). The T1 re-
laxivities were determined by the linear regression analysis of the water
proton relaxation rates in solutions ranging in concentration from 0.2 to
21 mm, HEPES buffer (50 mm), in triplicate. The NMRD profiles were
recorded with samples (1 mm) over a continuum of magnetic field
strengths from 0.00024 to 0.47 T (corresponding to 0.01–20MHz proton
Larmor Frequency) at 25 8C by using a Stelar field-cycling relaxometer
under computer control with an absolute uncertainty of 1%. Relaxation
data covering the range 0.47 T (20MHz) to 1.7 T (70MHz) were collect-
ed by using a Stelar Spinmaster spectrometer operating at variable fields.
Variable temperature 17O NMR measurements : 17O NMR linewidth data
were collected by using a Bruker DRX 600 NMR (14.1 T) spectrometer
equipped with a 5 mm probe and a Bruker VT-1000 thermocontroller.
NMR data were acquired by using a spectral width of 10000 Hz, a 908
pulse (7 ms), an acquisition time of 10 ms, 1000 scans and no sample spin-
ning. Water enriched in 17O to 2.6% (Yeda, Israel) was used. The ob-
served transverse relaxation rates (RO2obs) were calculated from the signal
width at half-height (Dn1/2): R
O
2obs=pDn1/2. The paramagnetic contribu-
tion to the water 17O transverse relaxation rate (RO2p) was calculated
from the RO2obs values according to the following equation: R
O
2p=
RO2obsRO2d, where RO2d is the water 17O transverse relaxation rate in the
absence of a GdL complex. The concentrations of Gd(3) and Gd(6) used
for 17O NMR measurements were 21 and 19 mm, respectively.
In vitro cell experiments : Rat 9L glioma cells were grown to confluence
in Dulbeccos Modified Eagle Medium (DMEM) supplemented with
fetal bovine serum (10%), l-glutamine (1%) and penicillin/streptomycin
(1%). The growth medium was replaced with un-supplemented DMEM
(8 mL) prior to the uptake experiment. One plate (100 mm i.d.) of cells
was made hypoxic by being exposed to nitrogen gas (1 Lmin1) in an en-
closed chamber for 2 h at room temperature and two other plates were
exposed to air. PBS (1 mL) was then added to one of the two normoxic
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samples (as negative control), and 1 mL of Gd(3) (45 mm) was added to
the remaining two samples (one normoxic and one hypoxic) to yield
a final concentration of 5 mm. The same procedure was followed to pre-
pare three other samples (control, normoxic and hypoxic) for assessing
cell uptake of Gd(6). These samples were incubated for 2 h at room tem-
perature (negative control and reference samples in air, hypoxic sample
in nitrogen at 1 Lmin1), rinsed three times with PBS, trypsinized to re-
lease the cells, and centrifuged in 15 mL tubes at 2500 rpm&&please
give in g&& for 5 min. Excess buffer was removed from the pellets, and
the samples were transferred to 0.2 mL tubes for a final centrifugation at
14500 rpm&&please give in g&& for 5 min.
MRI imaging of cells : The three sample tubes were positioned in a 2 cm
volume coil and imaged at 4.7 T. Images were collected by using a TE of
12 ms and ten different TR values ranging from (0.1–6 s). A T1 map was
computed on a voxel-by-voxel basis from a least-squares fitting of the ex-
ponential relaxation curves by using Varian software (VNMR 6.1C).
With the use of software written in MATLAB, a region of interest (ROI)
analysis was performed to extract voxel T1 values for each pellet for stat-
istical comparisons. The voxel T1 data were imported into Origin 6.1
(OriginLab, Northampton, MA, USA) for student t-test analyses.
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Imaging Agents
F. A. Rojas-Quijano, G. Tircs,*
E. Tircsn Beny, Z. Baranyai,
H. Tran Hoang, F. K. Klmn,
P. K. Gulaka, V. D. Kodibagkar,
S. Aime, Z. Kovcs,
A. D. Sherry* . . . . . . . . . . . . . . . . . &&&&—&&&&
Synthesis and Characterization of
a Hypoxia-Sensitive MRI Probe
Gd kill hunting : DO3A-monoamide
ligand with 2-nitroimidazole moiety
was synthesized &&(see structure)&
& with an aim to sequester the GdIII
ion and to target and visualize hypoxic
cells by using the MRI technique. In
vitro MRI experiments revealed that
the conjugate might be suitable for
assessment of hypoxia in vivo as the
agent was selectively trapped in
hypoxic (9L rat glioma) cells.
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